2026-05-30T19:52:54Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/48742021-11-10T09:38:19Zcom_10259_3924com_10259_5086com_10259_2604col_10259_3925
Repositorio Institucional de la Universidad de Burgos
author
Cossu, Claudia
author
Fiore, Michele
author
Baroni, Debora
author
Capurro, Valeria
author
Caci, Emanuela
author
García Valverde, María
author
Quesada Pato, Roberto
author
Moran, Óscar
2018-08-21T11:45:00Z
2018-08-21T11:45:00Z
2018-08
1663-9812
http://hdl.handle.net/10259/4874
10.3389/fphar.2018.00852
Cystic fibrosis (CF) is a genetic lethal disease, originated from the defective function
of the CFTR protein, a chloride and bicarbonate permeable transmembrane channel.
CF mutations affect CFTR protein through a variety of molecular mechanisms which
result in different functional defects. Current therapeutic approaches are targeted to
specific groups of patients that share a common functional defect. We seek to develop
an innovative therapeutic approach for the treatment of CF using anionophores, small
molecules that facilitate the transmembrane transport of anions. We have characterized
the anion transport mechanism of a synthetic molecule based on the structure of
prodigiosine, a red pigment produced by bacteria. Anionophore-driven chloride efflux
from large unilamellar vesicles is consistent with activity of an uniporter carrier that
facilitates the transport of anions through lipid membranes down the electrochemical
gradient. There are no evidences of transport coupling with protons. The selectivity
sequence of the prodigiosin inspired EH160 ionophore is formate > acetate > nitrate
> chloride > bicarbonate. Sulfate, phosphate, aspartate, isothionate, and gluconate are
not significantly transported by these anionophores. Protonation at acidic pH is important
for the transport capacity of the anionophore. This prodigiosin derived ionophore induces
anion transport in living cells. Its low toxicity and capacity to transport chloride and
bicarbonate, when applied at low concentration, constitute a promising starting point
for the development of drug candidates for CF therapy.
eng
Attribution 4.0 International
cystic fibrosis
ionophore
ion transport
phospholipid vesicles
prodigiosin derivatives
Anion-transport mechanism of a triazole-bearing derivative of prodigiosine: a candidate for cystic fibrosis therapy
info:eu-repo/semantics/article
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
URL
https://riubu.ubu.es/bitstream/10259/4874/1/Cossu-FP_2018.pdf
File
MD5
af675e628dac284c1edafee26a8eb99d
1878789
application/pdf
Cossu-FP_2018.pdf
URL
https://riubu.ubu.es/bitstream/10259/4874/6/Cossu-FP_2018.pdf.txt
File
MD5
6c671fbbb3b018f717fe9036cb86224e
69039
text/plain
Cossu-FP_2018.pdf.txt